Cipla Ltd.

NSE: CIPLA | BSE: 500087 | ISIN: INE059A01026 | Industry: Pharmaceuticals
| Mid-range Performer
1525.6000 -24.50 (-1.58%)
NSE May 02, 2025 15:31 PM
Volume: 2.0M
 

logo
Cipla Ltd.
16 Aug 2016
1525.60
-1.58%
Phillip Capital
Key highlights: Revenues grew 10% yoy at Rs35.94bn despite the integration of Invagen and that was 9% below our estimates. The miss in revenues was primarily due to no visible growth in Invagen portfolio, muted domestic as well as South African business. The margin performance at 17% (6.7% in Q4FY16) was almost in line of our expectations of 16.2% but the EBITDA missed our estimate by 4% due to lower sales.Thanks to lower tax incidence of 16% (vs 23% normal) that helped it report PAT of Rs 3.65bn (4% below estimated Rs 3.52bn). At a normalised tax rate, the profit performance was 7% below estimate. Phillip Capital retain their Neutral rating with lowered TP of Rs485.
Cipla Ltd. is trading above all available SMAs
More from Cipla Ltd.
Recommended